Democrats Take Control of Congress as Markets Assess Policy Outlook

Read the market coverage of this election and you could be forgiven for thinking voters had just ordered a fund rebalancing. Democrats take both chambers, and the question being asked in the financial press is which subsectors to buy. A healthcare analyst says to expect little change and to look at device makers near multiyear lows. Jim Cramer says the post-election rally was overdone and he's trimming data-center exposure. It's the rare election where the winners are discussed as a weather system.

This is how Wall Street processes democracy: as noise to be priced. The analyst's message is the soothing one: gridlock, nothing major for years, no reversals of recent rules. Investors hear that and exhale. Democrats should hear it and get angry.

Gridlock is a fine outcome for people whose position is already secure. If you own medical-device stock, stasis is a dividend. If you're a patient with a deductible you can't meet, or a household watching the power bill climb while a data-center campus goes up down the road, stasis is just the cost of living, billed monthly. Divided government doesn't mean nothing happens. It means the legislative path is narrow and the other tools matter more.

Those tools are real. Control of Congress means subpoenas, hearings, and the power of the purse. It means that the executive branch, which has spent years governing by announcement, now has to answer questions under oath. It means appropriations bills can no longer be written in the dark. A Democratic majority that treats this as a consolation prize will have wasted the one thing voters actually handed it.

The Cramer aside deserves more attention than it will get. His worry is data-center expansion: an AI buildout so large that it is moving markets and straining grids. Investors treat that as a question of whether the trade is crowded. The public question is who pays. Who absorbs the electricity demand, the water use, the tax abatements local governments signed in secret, and the rate increases that land on ordinary customers? These companies have been given extraordinary latitude, and a Congress that finally has investigative authority should ask what communities got in return. That is not anti-technology. It is the basic question of whether a public good, the grid, is being quietly converted into private infrastructure at public expense.

The same goes for healthcare. Yes, the analyst is probably right that the rules enacted in recent years won't be reversed soon, and that's worth saying plainly: the one durable thing in this picture is the Democratic legacy, drug-pricing reforms included. That should be a reason to defend it and extend it, not to congratulate ourselves on a stalemate. Investors expect nothing to happen. Democrats' job is to make that expectation wrong where it counts: hearings on why insurers deny care, scrutiny of consolidation, and a clear message about the next round of cost-cutting they would pass the moment they had the votes.

There's also an uncomfortable lesson for my own side. Democrats have a long habit of explaining that they'd love to do more but the Senate won't let them. Now the excuse has a different shape: we only have one chamber's worth of leverage, or two chambers' worth against a hostile White House. Voters have heard it. They will accept it for exactly one cycle, and only from a party that visibly uses every lever it has.

Let the markets wobble. Their anxiety is not the measure of this election. The measure is whether, two years from now, a family in a data-center county or a hospital waiting room can point to something that changed because the majority changed hands. If the best report card is that investors stayed calm, we will have failed.